Clementia Appoints Industry Veteran Pierre Legault to its Board of Directors
Mr. Legault is an accomplished leader in the biopharmaceutical industry with a proven track record, serving as chief executive officer or chief financial officer, leading corporate and business development and creating significant value for a premier set of international biopharmaceutical companies. In addition, Mr. Legault has significant experience as a director, serving on the board of many private and public companies.
“We are very pleased to welcome Pierre to Clementia’s board of directors, where his broad experience in global finance, operations, business development and commercialization will be a valuable asset as we advance palovarotene in pivotal trials for fibrodysplasia ossificans progressiva and multiple osteochondromas and towards potential commercialization,” said
Mr. Legault is currently the chairman of
Prior to that, Mr. Legault served as the CEO of
Mr. Legault holds an MBA in marketing from
“I am excited to join Clementia at this important juncture, following the completion of a very successful initial public offering last summer and the recent initiation of a registration trial for palovarotene in FOP,” said Mr. Legault. “I believe that Clementia is well positioned for success, and I look forward to working with management and the board to ultimately bring palovarotene to patients.”
Clementia is a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company’s lead candidate palovarotene, a novel RARγ agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP), with additional clinical studies planned in multiple osteochondromas (MO, also known as hereditary multiple exostoses) and other diseases. For more information, please visit www.clementiapharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may include “forward-looking statements” within the meaning of the applicable securities laws. Each forward-looking statement contained in this press release is subject to known and unknown risks and uncertainties and other unknown factors that could cause actual results to differ materially from historical results and those expressed or implied by such statement. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Applicable risks and uncertainties include, among others, our ability to generate revenue and become profitable; the risks related to our heavy reliance on palovarotene, our only current product candidate; the risks associated with the development of palovarotene and any future product candidate, including the demonstration of efficacy and safety; our heavy dependence on licensed intellectual property, including our ability to source and maintain licenses from third-party owners; as well as the risks identified under the heading “Risk Factors” in our Prospectus on Form 424(b) filed with the
THRUST Investor Relations
Source: Clementia Pharmaceuticals Inc.